The role of the microbiome and the NLRP3 inflammasome in the gut and lung,Journal of Leukocyte Biology

当前位置： X-MOL 学术 › J. Leukoc. Biol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The role of the microbiome and the NLRP3 inflammasome in the gut and lung
Journal of Leukocyte Biology ( IF 3.6 ) Pub Date : 2020-08-17 , DOI: 10.1002/jlb.3mr0720-472rr
Chantal Donovan _{1,

2} , Gang Liu ₁ , Sj Shen ₁ , Jacqueline E Marshall ₁ , Richard Y Kim _{1,

2} , Charlotte A Alemao ₂ , Kurtis F Budden ₂ , Jaesung P Choi ₁ , Maija Kohonen-Corish ₃ , Emad M El-Omar ₄ , Ian A Yang ₅ , Philip M Hansbro _{1,

2}

Affiliation

The nucleotide‐binding oligomerization domain (NOD)‐like receptor (NLR) family, pyrin domain‐containing protein 3 (NLRP3) inflammasome, is one of the most well‐characterized inflammasomes, activated by pathogen‐associated molecular patterns and damage‐associated molecular patterns, including from commensal or pathogenic bacterial and viral infections. The NLRP3 inflammasome promotes inflammatory cell recruitment and regulates immune responses in tissues such as the gastrointestinal tract and the lung, and is involved in many diseases that affect the gut and lung. Recently, the microbiome in the gut and the lung, and the crosstalk between these organs (gut–lung axis), has been identified as a potential mechanism that may influence disease in a bidirectional manner. In this review, we focus on themes presented in this area at the 2019 World Congress on Inflammation. We discuss recent evidence on how the microbiome can affect NLRP3 inflammasome responses in the gut and lung, the role of this inflammasome in regulating gut and lung inflammation in disease, and its potential role in the gut–lung axis. We highlight the exponential increase in our understanding of the NLRP3 inflammasome due to the synthesis of the NLRP3 inflammasome inhibitor, MCC950, and propose future studies that may further elucidate the roles of the NLRP3 inflammasome in gut and lung diseases.

中文翻译：

微生物组和 NLRP3 炎症小体在肠道和肺中的作用

核苷酸结合寡聚化结构域 (NOD) 样受体 (NLR) 家族，含pyrin 结构域的蛋白 3 (NLRP3) 炎症小体是特征最明显的炎症小体之一，由病原体相关分子模式和损伤相关分子激活。模式，包括来自共生或致病细菌和病毒感染。NLRP3炎性体促进炎症细胞募集并调节胃肠道和肺等组织的免疫反应，并参与影响肠道和肺的许多疾病。最近，肠道和肺中的微生物组以及这些器官之间的串扰（肠-肺轴）已被确定为可能以双向方式影响疾病的潜在机制。在这次审查中，我们专注于在 2019 年世界炎症大会上提出的这一领域的主题。我们讨论了微生物组如何影响肠道和肺中 NLRP3 炎症小体反应的最新证据，该炎症小体在调节疾病中肠道和肺部炎症中的作用，及其在肠-肺轴中的潜在作用。我们强调，由于 NLRP3 炎症小体抑制剂 MCC950 的合成，我们对 NLRP3 炎症小体的理解呈指数增长，并提出未来的研究，以进一步阐明 NLRP3 炎症小体在肠道和肺部疾病中的作用。

更新日期：2020-08-27

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11